Abstract
A novel coronavirus recently identified in Wuhan, China (2019-nCoV) has expanded the number of highly pathogenic coronaviruses affecting humans. The 2019-nCoV represents a potential epidemic or pandemic threat, which requires a quick response for preparedness against this infection. The present report uses the informational spectrum methodology to identify the possible origin and natural host of the new virus, as well as putative therapeutic and vaccine targets. The performed in silico analysis indicates that the newly emerging 2019-nCoV is closely related to severe acute respiratory syndrome (SARS)-CoV and, to a lesser degree, Middle East respiratory syndrome (MERS)-CoV. Moreover, the well-known SARS-CoV receptor (ACE2) might be a putative receptor for the novel virus as well. Actin protein was also suggested as a host factor that participates in cell entry and pathogenesis of 2019-nCoV; therefore, drugs modulating biological activity of this protein (e.g. ibuprofen) were suggested as potential candidates for treatment of this viral infection. Additional results indicated that civets and poultry are potential candidates for the
natural reservoir of the 2019-nCoV, and that domain 288-330 of S1 protein from the 2019-nCoV represents promising therapeutic and/or vaccine target.

**Keywords**
2019-nCoV, Wuhan coronavirus, SARS, MERS

This article is included in the Disease Outbreaks gateway.

This article is included in the Coronavirus collection.

---

**Corresponding author:** Veljko Veljkovic (eveljkve@gmail.com)

**Author roles:** Veljkovic V: Conceptualization, Formal Analysis, Methodology, Writing – Original Draft Preparation; Vergara-Alert J: Investigation, Writing – Original Draft Preparation; Segalés J: Investigation, Supervision, Writing – Original Draft Preparation; Paessler S: Investigation, Supervision, Writing – Original Draft Preparation

**Competing interests:** No competing interests were disclosed.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2020 Veljkovic V et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Veljkovic V, Vergara-Alert J, Segalés J and Paessler S. Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target [version 2; peer review: 1 approved, 1 approved with reservations] F1000Research 2020, 9:52
https://doi.org/10.12688/f1000research.22149.2

**First published:** 27 Jan 2020, 9:52 https://doi.org/10.12688/f1000research.22149.1

---

2. **Maria Salvato**<sup>1</sup>, University of Maryland, Baltimore, USA
STARBIOS2 (EU-funded consortium), Baltimore, USA

Any reports and responses or comments on the article can be found at the end of the article.
Introduction

Fears are mounting worldwide over the cross-border spread of the new strain of coronavirus (denoted as 2019-nCoV) originated in Wuhan, the largest city in central China, after its spread to Thailand and Japan. The newly emerging pathogen belongs to the same virus family as the deadly severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS-CoV and MERS-CoV, respectively). The World Health Organization (WHO) has recently published surveillance recommendations for a possible “large epidemic or even pandemic” of the novel coronavirus and it has issued guidelines for hospitals across the world. However, many questions about 2019-nCoV remain unanswered: (i) what is the origin and/or natural reservoir of the virus? (ii) is it easily transmitted from human to human? and (iii) what are the potential diagnostic, therapeutic and vaccine targets? Currently, only nucleotide sequences of eight human 2019-nCoV isolates are available without any additional information about biological properties of the virus, beyond the morphology confirmation of the virion using electronic microscopy. This is likely not enough information to answer the important abovementioned questions.

The informational spectrum method (ISM), a virtual spectroscopy method for analysis of proteins, is based on the fundamental electronic properties of amino acids and requires only nucleotide sequence availability to investigate proteins. For this reason, ISM was previously used for analysis of novel viruses for which little or no information were available. Here, the 2019-nCoV was analyzed with ISM to identify its possible origin and natural host, as well as putative therapeutic and vaccine targets.

Methods

Sequences

The S1 surface protein sequences from 8 human 2019-nCoV, deposited in the publicly available GISAID database (assessed on January 19, 2020), were analyzed by ISM. The studied sequences were BetaCoV/Wuhan/IVDC-HB-04/2020, BetaCoV/Wuhan/IVDC-HB-01/2019, BetaCoV/Wuhan/IVDC-HB-05/2019, BetaCoV/Wuhan/PPBCAMS-WH-01/2019, BetaCoV/Wuhan/WIV04/2019, BetaCoV/Wuhan-Hu-1/2019, BetaCoV/Nonthaburi/61/2020, and BetaCoV/Nonthaburi/74/2020.

In the phylogenetic analysis, different amino acid sequences of other coronaviruses were also included: (i) S1 proteins from the following viruses: AY559093, JX163927, YN2018B, KY417146, used already by other authors in the study of the phylogenetic relationship between 2019-nCoV and nearest bat and SARS-like CoVs (GISAID database); and (ii) S1 proteins from three first isolated human MERS-CoV: AGG22542, AF588936, AFY13307, deposited in the GISAID database.

The ISM

Detailed description of the sequence analysis based on ISM has been published elsewhere. According to this approach, sequences (protein or DNA) are transformed into signals by assignment of numerical values of each element (amino acid or nucleotide). These values correspond to electron-ion interaction potential, determining electronic properties of amino acid/nucleotides, which are essential for their intermolecular interactions. The signal obtained is then decomposed in a periodical function by the Fourier transformation. The result is a series of frequencies and their amplitudes. The obtained frequencies correspond to the distribution of structural motifs (primary structure) with defined physico-chemical characteristics responsible for the biological function of the putative protein corresponding to the analyzed sequence. When comparing proteins that share same biological or biochemical function, the technique allows detection of code/frequency pairs that are specific for their common biological properties. The method is insensitive to the location of the motifs and, therefore, does not require previous alignment of the sequences. In addition, this is the only method that allows immediate functional analysis.

Phylogenetic analysis

The phylogenetic tree of S1 proteins from coronaviruses was generated with the ISM-based phylogenetic algorithm ISTREE, previously described in detail elsewhere. In the presented analysis, we calculated the distance matrix with the amplitude on the frequency F(0.257) as the distance measure between sequences.

Results and discussion

In order to compare informational similarity between 2019-nCoV, SARS-CoV, MERS-CoV and Bat SARS-like CoV, the cross-spectra (CS) of S1 proteins from these viruses were calculated. Figure 1a shows the CS of 2019-nCoV, SARS-CoV and MERS-CoV. These CS contain only one dominant peak corresponding to the frequency F(0.257). Figure 1b displays the CS of S1 proteins from 2019-nCoV and Bat SARS-like CoV. Amplitudes in these latter CS are significantly lower than in those CS presented in Figure 1a. These results show that (i) S1 proteins from 2019-nCoV, SARS-CoV, MERS-CoV and Bat SARS-like CoV encode common information, which is represented with the frequency F(0.257), and (ii) S1 proteins from 2019-nCoV are remarkable more informationally similar with S1 from SARS-CoV and MERS-CoV than with S1 from Bat SARS-like CoV. This suggests that biological properties of 2019-nCoV are apparently more similar to SARS-CoV and MERS-CoV than to Bat SARS-like CoV.

To confirm this conclusion, the ISM-base phylogenetic tree for S1 proteins was calculated (Figure 2). In this calculation the amplitude on the frequency F(0.257) was used as the distance measure. As observed in Figure 2, all analyzed
2019-nCoV S1 amino acid sequences are grouped with SARS-CoV and MERS-CoV and separated from Bat SARS-like CoV. This indicates that 2019-nCoV are more phylogenetically similar to SARS-CoV and MERS-CoV than to Bat SARS-like CoV. This result differs from those obtained with the homology-based phylogenetic analysis, which showed that 2019-CoV are closely related to Bat SARS-like CoV (https://platform.gisaid.org/epi3/frontend#lightbox1296857287).

It has been previously shown that the dominant frequency in the informational spectrum of viral envelope proteins corresponds to interaction between the virus and its receptor.\(^2,8,9\) The ISM analysis showed that the frequency component $F(0.257)$ is present in the CS of S1 SARS-CoV and its receptor angiotensin converting enzyme 2 (ACE2),\(^2\) but not in the CS of S1 MERS-CoV and its main receptor dipeptidyl peptidase 4 (DPP4).\(^7\) Of note is that both receptors ACE2 and DPP4 are expressed in airway epithelia. Presence of $F(0.257)$ in the informational spectrum of MERS-CoV (Figure 1) suggests also possible interaction between this virus and the ACE2. The dominant peak on the frequency $F(0.257)$ in the CS of S1 from SARS-CoV and MERS-CoV and ACE2 supports this possibility (Figure 3), although this has not been formally proved for MERS-CoV.\(^1\)

As it is shown in Figure 1a, the frequency $F(0.257)$ is also present in the informational spectrum of the 2019-nCoV, suggesting that ACE2 might be the receptor for this novel coronavirus too. Calculation of the CS for S1 protein from the 2019-nCoV and all ACE2 sequences available at the UniProt database revealed that the highest amplitudes on the frequency $F(0.257)$ correspond to ACE2 from civet and chicken. This result indicates that these species can be included as potential candidates for the natural reservoir of the 2019-nCoV. However, it is possible that 2019-nCoV viruses use very different receptors in the natural host(s) and not only the ACE2 as it is the putative case in humans.

Finally, the S1 amino acid sequence from the 2019-nCoV was scanned to look for the domain that gives the highest contribution to the information represented by the frequency $F(0.257)$ (Figure 4a). This analysis revealed domain 266–330
Figure 3. Cross-spectrum of ACE2 and S1 proteins from SARS-CoV and MERS-CoV. The abscissa and the ordinate are as described in Figure 1.

Figure 4. Domain of S1 protein which is important for 2019-nCoV/ACE2 interaction. (a) Mapping of the domain of S1 protein from 2019-nCoV (BetaCoV/Wuhan/IVDC-HB-01/2019) which gives the dominant contribution to the information represented with the frequency F(0.257). (b) Sequence homology between domains of S1 proteins from SARS-CoV and 2019-nCoV with essential contribution to the information corresponding to the frequency F(0.257).

(numbering concerns the maturated protein) is essential for interaction of 2019-nCoV with ACE2. Of note is the striking homology between these domains of S1 proteins from 2019-nCoV and SARS-CoV, but not from MERS-CoV for which ACE2 is not the main receptor (Figure 4b).

Further, S1 spike proteins from SARS-CoV (Table 1) and 2019-nCoV (Table 2) were compared. The CS of S1 proteins from SARS-CoV (Figure 5a) and 2019-nCoV (Figure 5b) were assessed. Principal information encoded in S1 proteins from SARS-CoV and 2019-nCoV is represented with two different frequencies.
Table 1. S1 proteins from SARS_CoV (uniprot.org).

| Protein          | Description                           | Species          |
|------------------|---------------------------------------|------------------|
| SPIKE_CVHSA      | Spike glycoprotein OS=Human SARS coronavirus |
| Q19QX0_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| A7J8L4_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| J9SFL2_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| J9TDZ0_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202F4_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202E5_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202E9_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202F5_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202E6_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202H5_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202F2_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202F9_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202G8_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202G3_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202H8_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |
| Q202G5_CVHSA     | Spike glycoprotein OS=Human SARS coronavirus |

Table 2. S1 proteins from 2019-nCoV (GISAID).

| Protein          | Description                           | Species          |
|------------------|---------------------------------------|------------------|
| BetaCoV/Wuhan/IVDC-HB-04/2020 |                                |
| BetaCoV/Wuhan/IVDC-HB-01/2019   |                                |
| BetaCoV/Wuhan/IVDC-HB-05/2019   |                                |
| BetaCoV/Wuhan/IPBCAMS-WH-01/2019|                                |
| BetaCoV/Wuhan/Hu-1/2019        |                                |
| BetaCoV/Nonthaburi/61/2020     |                                |
| BetaCoV/Nonthaburi/74/2020     |                                |
| BetaCoV/Wuhan/WIV07/2019       |                                |
| BetaCoV/Wuhan/WIV06/2019       |                                |
| BetaCoV/Wuhan/WIV05/2019       |                                |
| BetaCoV/Wuhan/WIV02/2019       |                                |
| BetaCoV/Wuhan/HBCDC-HB-01/2019 |                                |
| BetaCoV/Zhejiang/WZ-01/2020    |                                |

F(0.222) and F(0.478), respectively. This result indicates some potential difference(s) in the virus-host interaction of these two viruses although they apparently use the same receptor ACE2.

To identify the host proteins involved in the attachment and/or internalization of the 2019-nCoV, the UniProt database (https://www.uniprot.org) was screened by ISM for human proteins with the dominant peak on the frequency F(0.478). The list of human proteins that have a dominant peak in IS at the frequency F(0.478) are given in Table 3. According to the IS criterion, these proteins are potential candidate interactors with the 2019-nCoV S1 protein. Further, literature data mining was performed to identify which proteins presented in Table 3 might be involved in the processes of infection with human coronaviruses. This analysis revealed that the actin protein plays an important role in the early entry events during human coronavirus infections12. Actin proteins were selected as the best candidate interactors for the 2019-nCoV among the host proteins that are characterized with frequency F(0.478). Figure 5c shows that CS of actins from different mammalian species (Table 4) contains the dominant peak on F(0.478), suggesting that these proteins probably encode...
Figure 5. CS of S1 proteins from SARS-CoV and 2019-nCoV and actin proteins. (a) CS of S1 proteins from human SARS-CoV; (b) CS of S1 proteins from 2019-nCoV; (c) CS of mammalian actin proteins. The abscissa and the ordinate are as described in Figure 1.

The conserved information important for their biological function.

The data mining of the PubMed database (www.ncbi.nlm.nih.gov/pubmed/) also showed that actin protein plays an important role in the rapid virus cell-to-cell spread and dissemination of infection\(^1\). Additionally, the actin filament reorganization is a key step in lung inflammation induced by systemic inflammatory responses caused by infectious agents\(^1\). These findings indicate that interaction between actin proteins and the S1 could be involved in the infection and pathogenesis of 2019-nCoV. In consequence, the possibility to interfere on this interaction might represent a valid hypothesis for development of promising prevention and therapeutic strategies.

Interestingly, further data mining revealed that ibuprofen (FDA approved drug with excellent safety record) attenuates interleukin-1β-induced inflammation as well as actin reorganization\(^1\). Actin was also found to be the primary component by which ibuprofen can bind to the tissue in different organs\(^3\). This suggests that ibuprofen might impact the 2019-nCoV-induced disease by indirect interaction with actin proteins. Previously, ibuprofen was predicted as a candidate entry inhibitor for Ebola virus using the same in silico approach\(^4\), and this prediction was confirmed experimentally at a later time point\(^5,6\). These results prompt the possibility to experimentally test the effects of ibuprofen on 2019-nCoV infection under in vitro and in vivo conditions.

In silico methods are considered very important tools to generate first hypotheses and identify first drug candidates against newly discovered agents, like in the case of 2019-nCoV, especially in the short-term. ISM, a technology based on electronic biology, allowed identifying potential importance of human actin proteins for viral infection/dissemination as well as one FDA approved drug that may have an indirect antiviral activity within weeks of the initial outbreak. However, additional experiments are required to confirm our initial findings.

In conclusion, results of the presented in silico analysis suggest the following: (i) the newly emerging 2019-nCoV is highly related to SARS-CoV and, to a lesser degree,
Table 3. Human proteins ([uniprot.org](http://uniprot.org)) with the dominant peak on the frequency $F(0.478)$ in the informational spectrum.

| Protein Name | Description | Species |
|--------------|-------------|---------|
| ABCB8_HUMAN | ATP-binding cassette sub-family B member 8 | Human |
| ACTB_HUMAN | Actin, cytoplasmic 1 | Human |
| ACTC_HUMAN | Actin, alpha cardiac muscle 1 | Human |
| ACTK_HUMAN | Kappa-actin | Human |
| ACTS_HUMAN | Actin, alpha skeletal muscle | Human |
| ATL3_HUMAN | ADAMTS-like protein 3 | Human |
| AUP1_HUMAN | Ancient ubiquitous protein 1 | Human |
| CA064_HUMAN | Putative uncharacterized protein C1orf64 | Human |
| CETN2_HUMAN | Centrin-2 | Human |
| CPNE1_HUMAN | Copine-1 | Human |
| CR034_HUMAN | Uncharacterized protein C18orf34 | Human |
| CSEN_HUMAN | Calsenilin | Human |
| EXOC4_HUMAN | Exocyst complex component 4 | Human |
| F108B_HUMAN | Abhydrolase domain-containing protein FAM108B1 | Human |
| FGF13_HUMAN | Fibroblast growth factor 13 | Human |
| FRMD1_HUMAN | FERM domain-containing protein 1 | Human |
| GCDH_HUMAN | Glutaryl-CoA dehydrogenase, mitochondrial | Human |
| GKN2_HUMAN | Gastrokine-2 | Human |
| GPDA_HUMAN | Glycerol-3-phosphate dehydrogenase [NAD+] | Human |
| HPS1_HUMAN | Hermansky-Pudlak syndrome 1 protein | Human |
| HXK3_HUMAN | Hexokinase-3 | Human |
| IL23R_HUMAN | Interleukin-23 receptor | Human |
| KAD3_HUMAN | GTP:AMP phosphotransferase mitochondrial | Human |
| KRA71_HUMAN | Keratin-associated protein 7-1 | Human |
| LGMN_HUMAN | Legumain | Human |
| MYOG_HUMAN | Myogenin | Human |
| NTR2_HUMAN | Neurotensin receptor type 2 | Human |
| RD3_HUMAN | Protein RD3 | Human |
| S2543_HUMAN | Solute carrier family 25 member 43 | Human |
| SMDF_HUMAN | Neuregulin-1, sensory and motor neuron-derived factor | Human |
| SOX17_HUMAN | Transcription factor SOX-17 | Human |
| THOC4_HUMAN | THO complex subunit 4 | Human |
| TXND1_HUMAN | Thioredoxin domain-containing protein 1 | Human |
| VATE2_HUMAN | Vacuolar ATP synthase subunit E 2 | Human |
| ZN516_HUMAN | Zinc finger protein 516 | Human |
Table 4. Mammalian actin proteins (uniprot.org).

| Protein Name          | Description                           | Organism          |
|-----------------------|---------------------------------------|-------------------|
| ACTB_HUMAN            | Actin cytoplasmic 1                    | Homo sapiens      |
| ACTB_MOUSE            | Actin cytoplasmic 1                    | Mus musculus      |
| ACTC_HUMAN            | Actin alpha cardiac muscle 1          | Homo sapiens      |
| ACTB_CAVPO            | Actin cytoplasmic 1                    | Cavia porcellus   |
| ACTS_MOUSE            | Actin alpha skeletal muscle            | Mus musculus      |
| ACTB_PONAB            | Actin cytoplasmic 1                    | Pongo abelii      |
| ACTA_MOUSE            | Actin aortic smooth muscle             | Mus musculus      |
| ACTH_MOUSE            | Actin gamma-enteric smooth muscle      | Mus musculus      |
| ACTG_MOUSE            | Actin cytoplasmic 2                    | Mus musculus      |
| ACTB_MESAU            | Actin cytoplasmic 1                    | Mesocricetus auratus |
| ACTG_HUMAN            | Actin cytoplasmic 2                    | Homo sapiens      |
| ACTS_RABIT            | Actin alpha skeletal muscle            | Oryctolagus cuniculus |
| ACTH_HUMAN            | Actin gamma-enteric smooth muscle      | Homo sapiens      |
| ACTC_MOUSE            | Actin alpha cardiac muscle             | Mus musculus      |
| ACTA_RAT              | Actin alpha cardiac muscle             | Rattus norvegicus |
| ACTG_RAT              | Actin cytoplasmic 2                    | Rattus norvegicus |
| ACTB_RAT              | Actin cytoplasmic 1                    | Rattus norvegicus |
| ACTB_BOVIN            | Actin cytoplasmic 1                    | Bos taurus        |
| ACTS_HUMAN            | Actin alpha skeletal muscle            | Homo sapiens      |

MERS-CoV, and ACE2 is a likely receptor of it; (ii) civets and poultry are potential candidates for the natural reservoir of the 2019-nCoV, (iii) human actin proteins possibly participate in attachment/internalisation of 2019-nCoV, (iv) drugs which interact with actin proteins (e.g. ibuprofen) should be investigated as possible therapeutics for treatment of 2019-nCoV infection, and (v) domain 266-330 of S1 protein from the 2019-nCoV represents promising therapeutic and/or vaccine target. Further research on these issues are needed, including the development of reverse genetics and animal models to study the biology of 2019-nCoV.

Data availability

Underlying data

Sequence data of the viruses were obtained from the GISAID EpiFlu™ Database. To access the database each individual user should complete the “Registration Form For Individual Users”, which is available alongside detailed instructions. After submission of the Registration form, the user will receive a password. There are not any other restrictions for the access to GISAID. Conditions of access to, and use of, the GISAID EpiFlu™ Database and Data are defined by the Terms of Use.

References

1. Veljković V, Cosić I, Dimitrijević B, et al.: Is it possible to analyze DNA and protein sequences by the methods of digital signal processing? IEEE Trans Biomed Eng. 1985; 32(5): 337–41. PubMed Abstract | Publisher Full Text
2. Veljković V, Niman HL, Glisic S, et al.: Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor. BMC Struct Biol. 2009; 9: 62. PubMed Abstract | Publisher Full Text | Free Full Text
3. Veljkovic V, Glisic S, Muller CP, et al.: In silico analysis suggests interaction between Ebola virus and the extracellular matrix. Front Microbiol. 2015; 6: 135. PubMed Abstract | Publisher Full Text | Free Full Text
4. Passler S, Veljkovic V: Prediction of influenza vaccine effectiveness for the influenza season 2017/18 in the US [version 1; peer review: 2 approved]. F1000Res. 2017; 6: 2067. PubMed Abstract | Publisher Full Text | Free Full Text
5. Koma T, Veljkovic V, Anderson DE, et al.: Zika virus infection elicits auto-antibodies to C1q. Sci Rep. 2018; 8(1): 1882. PubMed Abstract | Publisher Full Text | Free Full Text

6. Veljković V, Slavić I: Simple general-model pseudopotential. Phys Rev Let. 1972; 29: 105. Publisher Full Text

7. Perovic VR, Muller CP, Niman HL, et al.: Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIv reveals evolution toward efficient human-to-human transmission. PLoS One. 2013; 8(4): e61572. PubMed Abstract | Publisher Full Text | Free Full Text

8. Schmier S, Mostafa A, Haarmann T, et al.: In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A Viruses. Sci Rep. 2015; 5: 11434. PubMed Abstract | Publisher Full Text | Free Full Text

9. Li W, Moore MJ, Vasilieva N, et al.: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965): 450–4. PubMed Abstract | Publisher Full Text

10. Raj VS, Mou H, Smits SL, et al.: Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 499(7440): 251–4. PubMed Abstract | Publisher Full Text

11. Müller MA, Raj VS, Muth D, et al.: Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. mBio. 2012; 3(6): pii: e00515-12. PubMed Abstract | Publisher Full Text | Free Full Text

12. Owczarek K, Szczepanski A, Milewska A, et al.: Early events during human coronavirus OC43 entry to the cell. Sci Rep. 2018; 8(1): 7124. PubMed Abstract | Publisher Full Text | Free Full Text
This manuscript presents a machine-learning analysis of the published sequences of the novel 2019-nCoV. The authors use the Informational Spectrum Method (ISM), a virtual spectroscopy method for protein analysis based on the electronic properties of each amino acid. Their goal is to identify sites on the virus most likely to interact with other molecules like drugs, antibodies or viral receptors.

Due to the rapidity of this field and the time elapsed since the manuscript was submitted (Jan 27), most of their conclusions are no longer new: nCoV is most related to SARS-CoV and less to MERS-CoV, ACE2 is a likely receptor, the natural reservoir might be civets and poultry, human actin proteins participate in internalization, ibuprofen that interacts with actin proteins should be investigated as a therapeutic, and finally that domain 266-330 of the S1 protein should be targeted by drugs or vaccines.

It is a nice piece of work. The conclusions could be updated, for example they could say that the first of these predictions are supported by recent publications, that bat CoVs now appear to be the most closely related and bats are more likely to be the natural reservoir, and the link between ibuprofen/actin interactions and viral entry remains an exciting path for future therapeutics.

Minor corrections

○ In the first sentence of “Update” the authors refer to ‘these proteins’...do they mean Actin and SARS-CoV proteins? If they only mean actin they should say so, and then the sentence would read: “...actin protein is suggested as a host factor that participates in infection and pathogenesis of 2019-nCoV. Drugs modulating the biological activity of actin (e.g., ibuprofen) were suggested as candidates that should be investigated for the treatment of 2019-nCoV infection."

○ In the UPDATE, last sentences should say "...which are presented in Figure 5."
Introduction pg 3 “Fears are mounting worldwide over the cross-border spread of the new strain of coronavirus (denoted as 2019-nCoV) originated in Wuhan….” Instead say “…that originated in Wuhan…”

Introduction pg 3 “…eight human 2019-nCoV isolates are available without any additional information about biological properties of the virus, beyond the morphological confirmation…” Replace “morphology” with “morphological”, it is an adjective.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunology, viral pathogenesis, viral genetics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 18 March 2020

https://doi.org/10.5256/f1000research.24526.r60149

© 2020 Casadio R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rita Casadio
Biocomputing Group, CIG, Interdepartmental Center «Luigi Galvani» for Integrated Studies of
Bioinformatics, Biophysics and Biocomplexity, University of Bologna, Bologna, Italy

Possibly the ISM method invented by the authors has high potentiality. Here, apparently, the method is applied to answer urgent questions in relation to sequence analysis of the novel coronavirus 2019-nCoV. It is interesting to verify that different papers at the moment seem to have reached the same conclusions, although in my opinion a comparison with other methods which are already published would add to the paper. On top, R.Yan et al, Science 2020 4 March, beautifully detailed the putative region of the virus/ACE2 interaction. I recommend the authors quote this finding as well and if possible add the reference. This would help in validating a quite interesting method of sequence analysis.

References
1. Yan R, Zhang Y, Li Y, Xia L, et al.: Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020. PubMed Abstract | Publisher Full Text

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Computational Biology, Structural bioinformatics, Functional annotation, Machine and deep learning

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com